First Author: E.Krall AUSTRIA
Co Author(s): O. Seyeddain J. Stoiber A. Dexl G. Grabner J. Ruckhofer
Purpose:
To evaluate the efficacy, predictability, stability, and potential complications after implantation of a foldable iris-fixated toric phakic intraocular lens (pIOL) to correct myopic astigmatism.
Setting:
: University Eye Clinic, Paracelsus Medical University, Salzburg, Austria.
Methods:
The study assessed eyes having had an implantation of an ArtiflexTM toric pIOL with spherical power ranging from -1.0 to -13.5 diopters (D) and additional cylinder from -1.0 to -5.0 D, both in 0.5 D increments. All surgeries were performed by one experienced surgeon (GG). The main parameters were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, stability of manifest refraction. An anterior segment evaluation (slitlamp biomicroscopy), a tonometry, and a central endothelial cell count (ECC) were also performed.
Results:
The study enrolled 56 eyes of 29 patients with a mean age of 35 years (range 18 to 52 years), a mean spherical equivalent (SE) of -7.94 ± 2.33 diopters (dpt) (range -2.63 to -13.69 dpt), and a mean preoperative cylinder of -1.99 ± 0.94 dpt (range -1.0 to -5.0 D). Twelve months postoperatively the UDVA (Snellen lines) was 1.0 or better in 50 eyes (89%). The CDVA improved by 1 line in 27 eyes (48%) and by 2 or more lines in 12 eyes (22%) with no eye losing a line. All eyes were within ±0.50 dpt of the target refraction (SE), the mean refractive astigmatism was +0.21 ± 0.28 dpt. Refraction was stable from one day postoperatively. There was not found an ECC loss, measured at 12 months postoperatively. There were no serious complications observed.
Conclusions:
After a one year follow-up, toric pIOL implantation was found to be effective, predictable, stable and safe for the correction of myopic astigmatism.
Financial Disclosure:
None
